- Conatus Pharmaceuticals (CNAT) says it's initiated dosing in Phase II clinical studies of Emricasan in patients with severe alcoholic hepatitis.
- The study is designed to assess whether Emricasan improves the 28-day survival in patients with chronic liver disease caused by alcohol and contraindicated to receive corticosteroid therapy for their alcoholic hepatitis.
- It's being conducted by the Translational Research and Evolving Alcoholic Hepatitis Treatment Consortium consisting of the Mayo Clinic Rochester, Indiana University, and Virginia Commonwealth University in collaboration with the National Institute on Alcohol Abuse and Alcoholism.
- Shares +0.5% AH.
at Zacks.com (Nov 11, 2014)